BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1220 related articles for article (PubMed ID: 18467670)

  • 1. Characteristics of an ideal rotavirus vaccine.
    Reisinger KS; Block SL
    Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
    Chandran A; Santosham M
    Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotavirus vaccines: entering a new stage of deployment.
    Nakagomi O; Cunliffe NA
    Curr Opin Infect Dis; 2007 Oct; 20(5):501-7. PubMed ID: 17762784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
    Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
    Clark HF; Offit PA; Plotkin SA; Heaton PM
    Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.
    Heaton PM; Goveia MG; Miller JM; Offit P; Clark HF
    J Infect Dis; 2005 Sep; 192 Suppl 1():S17-21. PubMed ID: 16088800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
    Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
    Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
    Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated human rotavirus vaccine, Rotarix.
    Bernstein DI
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants.
    Bernstein DI; Sack DA; Reisinger K; Rothstein E; Ward RL
    J Infect Dis; 2002 Nov; 186(10):1487-9. PubMed ID: 12404166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
    Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.
    Goveia MG; Suprun L; Itzler RF; McFetridge R; Dallas MJ; Kuter BJ
    Pediatr Infect Dis J; 2010 Mar; 29(3):263-5. PubMed ID: 19949360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix.
    Nakagomi T; Nakagomi O
    Expert Opin Biol Ther; 2009 Aug; 9(8):1073-86. PubMed ID: 19591630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
    Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotavirus vaccines.
    Vesikari T
    Scand J Infect Dis; 2008; 40(9):691-5. PubMed ID: 19086243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.